Form D · Biotechnology

Carmot Therapeutics Inc.

Berkeley, CA · CIK 0001490109

Offering snapshot reported Jun 6, 2023 · SEC filing

Reported sold
$150M
Offering amount: $150M
Investors reported
25
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
May 24, 2023
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 6, 2023Initial$149,999,802No comparison25SEC filing
Aug 8, 2022Initial$160,671,809No comparison15SEC filing
Oct 1, 2020Initial$26,282,207No comparison6SEC filing
Aug 25, 2017Initial$10,795,943No comparison4SEC filing
Jul 17, 2012Initial$500,159No comparison2SEC filing
Apr 23, 2010Initial$1,549,999No comparison2SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-483450

Source: Form D, filed Jun 6, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Daniel A. Erlanson Director, Executive
Timothy Garnett Director
Dave Goeddel Director
Stig K. Hansen Director, Executive
Stig K. Hansen, Ph.D. Director
Tim Kutzkey Director
Tim Kutzky Director
Larry Lasky Director
Magnus Persson Director
Anne Phillips, M.D. Director
Peter Svennilson Director
Aetna Wun Trombley Director
Aetna Wun Trombley Director
Heather Turner Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
740 Heinz Avenue
Berkeley, CA, 94710